Skip to content
Screener

SG&A at other companies

Eli Lilly logo
Eli LillyLLY
$3.43B+24.6%
LQD
Liquidia CorporationLQDA
$46.94M+56.1%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$9.75M+4.3%
Kiniksa Pharmaceuticals International, plc logo
Kiniksa Pharmaceuticals International, plcKNSA
$63.87M+36.3%
Cytokinetics logo
CytokineticsCYTK
$104.4M+58.8%
Abbott logo
AbbottABT
$4.03B+30.2%

Other financials

Income statement

See full
Revenue$109.4M+42.9%
Gross profit$95.0M+32.0%
Operating income-$350.0K-107%
Net income-$19.0M-2,949%
EPS (diluted)-$0.06

Balance sheet

See full
Cash & equivalents$52.9M-7.2%
Total debt$11.8M-7.5%
Total equity-$67.2M-22.1%
Total assets$732.3M+77.9%

Cash flow

See full
Operating cash flow-$18.4M-305%
CapEx$5.1M+355%
Free cash flow-$23.5M-399%

Valuation

See full
Market cap$1.32B+25.9%
Enterprise value$1.28B+27.4%
P/S3.4×-0.1×

Profitability

See full
Gross margin89.8%-4.8pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity44.2%
Debt / equity-0.2×
Current ratio1.7×-0.8×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Mannkind’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335054
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Cost of goods sold – commercial, excluding amortization of acquired intangible assets14,4094,60721,9178,375
Cost of revenue – collaborations and services15,13115,96125,09429,709
Research and development18,00113,67535,23224,697
Selling, general and administrative58,30231,622112,38956,636
Amortization of acquired intangible assets4,3678,734
(Gain) loss on foreign currency transaction(486)5,363(1,804)7,872
Total expenses109,72471,228201,562127,289
(Loss) income from operations(350)5,299(2,018)27,592

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Mannkind's SG&A?
Mannkind (MNKD) reported SG&A of $58.3M in Q2 2026.
How has Mannkind's SG&A changed year-over-year?
Mannkind's SG&A increased by 84.4% year-over-year, from $31.62M to $58.3M.
What is the long-term trend for Mannkind's SG&A?
Over 4 years (2021 to 2025), Mannkind's SG&A has grown at a 16.8% compound annual growth rate (CAGR), from $77.42M to $144.14M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

Ask your AI about Mannkind's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude